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ABSTRACT.  
The present study aimed to evaluate the incorporation of protamine into niosome/DNA 
vectors to analyze the potential application of this novel ternary formulation to deliver the 
pCMS-EGFP plasmid into the rat retina. Binary vectors based on niosome/DNA and ternary 
vectors based on protamine/DNA/niosomes were prepared and physicochemically 
characterized. In vitro experiments were performed in ARPE-19 cells. At 1:1:5 
protamine/DNA/niosome mass ratio, the resulted ternary vectors had 150 nm size, positive 
charge, spherical morphology, and condensed, released, and protected the DNA against 
enzymatic digestion. The presence of protamine in the ternary vectors improved transfection 
efficiency, cell viability, and DNA condensation. After ocular administration, the EGFP 
expression was detected in different cell layers of the retina depending on the administration 
route without any sign of toxicity associated with the formulations. While subretinal 
administration transfected mainly photoreceptors and retinal pigment epithelial cells at the 
site of injection, intravitreal administration produced a more uniform distribution of the 
protein expression through the inner layers of the retina. The protein expression in the retina 
persisted for at least one month after both administrations. Our study highlights the flattering 
properties of protamine/DNA/niosome ternary vectors for efficient and safe gene delivery to 
the rat retina. 
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 INTRODUCTION 
Gene therapy represents a promising therapeutic approach to correct genetic 
deficiencies or to treat acquired diseases.
1
 The success of the therapy relies on the design of 
efficient delivery systems to introduce exogenous genetic materials into the target cells.
2
 
Nevertheless, gene replacement therapy is still far to be considered as a mainstream medicine 
option. Besides safety concerns, other relevant limitations such as the poor uptake of gene 
delivery vectors and the posterior gene expression, along with the attenuated expression of 
the gene over time, clearly jeopardize the clinical application. Therefore, many strategies are 
being explored by the research community to circumvent these issues.
3
  
Among the human organs, the eye has unique advantages for gene therapy purposes. 
In particular, its small size, immune privileged location, and well-defined compartmentalized 
anatomy enable local vector delivery of small volumes with low likelihood of systemic 
dissemination, minimizing the potential adverse reactions that may follow after intraocular 
injection of foreign antigens.
4
 Furthermore, since the media is transparent, the gene transfer 
process can be easily tracked through noninvasive techniques, and minor changes of visual 
function can be monitored by sensitive methods.
5
 Finally, most of the inherited diseases that 
cause irreversible blindness such as Retinitis Pigmentosa, Stargardt’s disease, Choroideremia, 
and Age-related Macular Degeneration are well localized mainly on retinal ganglion cells, 
photoreceptors, or retinal pigment epithelium6 and have a well-known genetic background. 
Despite these relevant advantages, few effective treatments are available at present for the 
treatment of inherited retinal diseases, and many of the affected patients must live under 
impaired vision, even with the best medical option. Therefore, research on retinal gene 
therapy offers hope and represents a logical and promising approach to develop new safe and 
effective gene based treatments to translate animal research into clinical trials.
6,7
  
Actually, retinal gene delivery systems can be classified in two main groups: viral and nonviral 
vectors. Even if engineered to minimize adverse biological effects, viral vectors may induce 
inflammation, immunogenicity, and secondary oncogenesis due to insertional mutagenesis.
8,9
 
These handicaps, along with the limited DNA carrying apacity, the high cost of production, and 
the negative public perception of viral vectors,
10−12
 have prompted the need to develop safer 
and biologically inactive nonviral strategies.
13
 Among nonviral vectors, cationic lipid/ DNA 
complexes (lipoplexes) have shown tangible successes in retinal gene delivery applications.
14−17
 
Recently, we elaborated novel niosomes based on the 2,3- di(tetradecyloxy)propan-1-
amine cationic lipid, combined with squalene and polysorbate 80, to transfect efficiently the 
rat retina with the pCMS-EGFP reporter plasmid.
18
 In a logical effort to progress and develop 
novel safe and efficient nonviral retinal gene delivery vectors, we have incorporated in the 
present study protamine to our niosome formulation to obtain protamine/DNA/niosome 
ternary vectors. Protamine is a peptide obtained from the sperm of salmon or herring with 
excellent properties for gene delivery purposes since it condenses DNA, and its rich sequences 
in arginine promote active nuclear transport.
19
 Additionally, protamine is a FDAapproved 
compound with a documented safety profile. However, it has been reported in the literature 
that protamine/ DNA vectors by themselves do not yield high levels of transfection efficiency 
20,21
 probably due to the high hydrophilicity of the protamine, which could hamper the entry 
through the cellular membrane.
21
 Therefore, protamine has been successfully incorporated 
mainly into lipid formulations such as liposome 
22,23
 and in the past few years into solid lipid 
nanoparticles to increase transfection efficiency.
24−26
 Consequently, we have hypothesized that 
the incorporation of protamine to our niosome formulation, at an appropriate proportion, 
might lead to the design of novel nonviral ternary vectors, with a nontoxic profile, that could 
transfect efficiently cells of the rat retina after intravitreal and subretinal injection. A 
schematic diagram of the structure of both binary and ternary vectors with the chemical 
compounds involved in the noisome formulation is represented in Figure 1 of the Supporting 
Information. 
To validate our hypotehsis, we used the reporter pCMSEGFP plasmid to elaborate 
binary and ternary vectors based on niosome/DNA and protamine/DNA/niosomes complexes 
respectively at different mass ratios (w/w). The resulting vectors were characterized in terms 
of size, zeta potential, morphology, and the ability to condense, protect the DNA from 
enzymatic digestion, and release the protected DNA. This information was critical to determine 
the optimal ratios for transfection. In vitro experiments were performed in ARPE-19 cells to 
evaluate the transfection efficiency, viability, and intracellular DNA trafficking. Finally, the 
most promising formulation was administered by subretinal and intravitreal injections to 
evaluate any sign of toxicity or damage associated with the administration of the formulation 
by spectral domain optical coherence tomography (SD-OCT) as well as the expression of the 
enhanced green fluorescent protein (EGFP) by immunohistochemistry analysis in different cells 
and layers of the retina. According to our knowledge, this is the first time that the 
incorporation of protamine at an appropriate proportion into cationic niosomes has been 
evaluated for retinal gene delivery purposes. 
 
2. MATERIALS AND METHODS 
 
2.1. Materials.  
The plasmid pCMS-EGFP, which encodes the EGFP, was propagated in Escherichia coli DH5-α 
and purified using the Qiagen endotoxin-free plasmid purification Maxi-prep kit (Qiagen, Santa 
Clarita, CA, USA) according to the manufacturer’s instructions. Concentration of pDNA was 
quantified by measuring absorbance at 260 nm using a NanoDrop (ND-1000 
Spectrophotometer, Thermo Fisher Scientific Inc. Denver, USA). The purity of the plasmid was 
verified by agarose gel electrophoresis in Tris Borate-EDTA buffer, pH 8.0 (TBE buffer). DNA 
bands were detected using GelRed (Biotium, Hayward, California, USA), and images were 
observed with a ChemiDoc MP Imaging System (Bio-Rad, 
USA). DNase I, sodium dodecyl sulfate (SDS), squalene, protamine sulfate, and PBS were 
purchased from Sigma-Aldrich (Madrid, Spain); dichloromethane was purchased from Panreac 
(Barcelona, Spain). The labeling of plasmid pCMS-EGFP with fluorescein isothiocyanate (FITC) 
and ethidium monoazide (EMA) was carried out by DareBio S.L (Elche, Spain). Hoechst 33342, 
Fluoromont G was from SouthernBiotech (Coultek, Spain). Dulbecco’s Modified Eagle’s 
medium−Hanks Nutrient Mixture F-12, Opti-MEM reduced medium, fetal bovine serum, 
antibiotic/antimicotic solution, Lipofectamine 2000, and 0.05% trypsin/EDTA were acquired 
from Invitrogen (San Diego, California, US). Polysorbate 80 (Tween 80) was provided by 
Vencaser (Bilbao, Spain). Retinal pigmented epithelial (ARPE-19) cells were obtained from the 
American Type Culture Collection (ATCC). The BD Viaprobe kit was provided by BD Biosciences 
(Belgium). 
 
2.2. Production of Cationic Niosomes and Preparation of Binary and Ternary Vectors.  
The cationic lipid 2,3- di(tetradecyloxy)propan-1-amine was synthesized by the experimental 
protocol described previously,
27
 and cationic niosomes based on the aforementioned lipid 
were elaborated by the solvent emulsification−evaporation technique.
18
 Niosome/DNA binary 
vectors were elaborated by mixing an appropriate volume of a pCMS-EGFP plasmid stock 
solution (0.5 mg/mL) with different volumes of the niosome suspension to obtain 
niosome/DNA binary vectors due to the electrostatic interactions between the incubated 
cationic niosomes and the negatively charged plasmid. The niosome/DNA ratio was expressed 
as the ratio of cationic lipid to DNA (w/w). Different niosome/DNA ratios were elaborated: 1:1, 
2:1, 5:1, 10:1, 15:1, and 30:1. Protamine/DNA/niosome ternary vectors were prepared by first 
binding protamine to DNA at different ratios (w/w). Briefly, an appropriate volume of a 
protamine solution (0.5 mg/mL) was vortexed for 30 s with different volumes of a pCMS-EGFP 
plasmid solution (0.5 mg/mL) to obtain different protamine/DNA ratios (w/w): 0.25:1, 0.5:1, 
1:1, 2:1, and 4:1. Complexes were incubated for 30 min at room temperature to enhance 
electrostatic interactions between the plasmid and the protamine. Thereafter, the 
protamine/DNA complexes were further mixed for 30 min with a suspension of the previously 
prepared niosomes, and electrostatic interactions between protamine/DNA complexes and 
niosomes led to the formation of the protamine/DNA/niosome ternary vectors. The proportion 
of each component was expressed as the protamine/ DNA/cationic lipid ratio (w/w/w). 
 
2.3. Physicochemical Characterization of Vectors. 
Both niosome/DNA binary vectors and protamine/DNA/ niosome ternary vectors were 
physicochemically characterized as described previously in terms of DNA condensation, DNA 
release upon the addition of SDS and DNA protection against DNase I enzymatic digestion.
28
 
Additionally, vectors were visualized by transmission electron microscopy (TEM), and the 
hydrodynamic diameter and superficial charge of resulting binary and ternary vectors were 
determined by dynamic light scattering (DLS) and laser Doppler velocimetry (LDV) respectively 
as elsewhere described.
29
 
 
2.4. In Vitro Transfection Assays.  
For transfection experiments, ARPE-19 cells were seeded in 24-well plates at an initial 
density of 7.5 × 10
4
 cells/well with 1 mL of D-MEM/ F-12 containing 10% fetal bovine serum 
(not antibiotic/ antimicotic). When confluence level reached 70−80%, the media was removed, 
and the cells were exposed to different formulations based on niosome/DNA and 
protamine/DNA/ niosomes vectors containing 1.25 μg of DNA per well. Vectors were diluted in 
serum-free Opti-MEM I solution and incubated with cells for 4 h at 37 °C. Following the 
incubation time, the medium was refreshed with 1 mL of complete growth medium, and cells 
were allowed to grow until fluorescence microscopy and flow cytometry analysis.  
Qualitative and quantitative expression of EGFP was examined by microscopy (Eclipse 
TE200-S, Nikon Instruments Europe B.V., Amstelveen, The Netherlands) and flow cytometry 
(Becton Dickinson Biosciences, San Jose, USA), respectively. Briefly, cells were washed twice 
with PBS and detached with 300 μL of 0.05% trypsin/EDTA. Then, cells were centrifuged, and 
the supernatant was discarded. The pellet was resuspended in PBS, diluted in FACS Flow liquid, 
and directly introduced in the flow cytometer. Transfection efficiency was expressed as the 
percentage of EGFP positive live cells at 525 nm (FL1). For cell viability measurements, the BD-
Via Probe reagent (5 μL) was added to each sample to exclude dead cells from the analysis. 
The fluorescence corresponding to dead cells was measured at 650 nm (FL3). Control samples 
(nontransfected cells) were displayed on a forward scatter (FSC) versus side scatter (SSC) dot 
plot to establish a collection gate and exclude cells debris. Other samples containing 
Lipofectamine transfected cells without BDVia Probe and nontransfected cells with BD-Via 
Probe were used as controls to compensate the FL2 signal in FL1 and FL3 channels. For each 
sample, 10 000 events were collected. 
 
2.5. Intracellular Distribution of DNA.  
DNA distribution inside the cells was evaluated 2 h after the addition of vectors 
carrying EMA-labeled DNA by fluorescence microscopy. Prior to the observation of the samples 
under an inverted fluorescence microscope (Eclipse TE 2000-S; Nikon Corporation, Tokyo, 
Japan), nuclei were labeled with Hoechst 33342. 
 
2.6. In Vivo Studies in Rats.  
Six adult male Sprague− Dawley rats (6−7 weeks old, 150−200 g weight) were injected 
intravitreally and other six rats subretinally. All experimental procedures were carried out in 
accordance with the Spanish and European Union regulations for the use of animals in 
research and the Association for Research in Vision and Ophthalmology (ARVO) statement for 
the use of animals in ophthalmic and vision research and supervised by the Miguel Hernandez 
University Standing Committee for Animal Use in Laboratory. The surgical procedures used for 
the administration of the vectors in the retina have been previously described elsewhere.
29
 
 
2.7. Optical Coherence Tomography (OCT).  
Noninvasive in vivo assessment of eye structures was performed using OCT (Spectralis 
HRA OCT system, Heidelberg Engineering). OCT was performed under general anesthesia 
induced with an intraperitoneal injection of ketamine (70 mg/ kg, Imalgene; Merial) and 
diazepam (5 mg/kg, Valium, Roche). Tropicamide 1% (Colircusi  Tropicamida, Alcon Cusi ) was 
dropped on the eyes to dilate the pupil and give access to a wide panoramic of the fundus. A 
custom-made contact lens (+25 Diopter) was used to reduce the risk of corneal dehydration 
and edema and to act as a collimator. Twentyfive b-scans with near-infrared (IR) imaging were 
obtained at standardized position around the optic nerve. All the animals were examined the 
previous day to the intravitreal or subretinal injections with the intact eyes. This protocol was 
repeated 14 days and one month postinjection. 
 
2.8. Analysis of EGFP Expression by Native GFP Fluorescence and Indirect 
Immunofluorescence.  
To analyze native GFP, whole-mount preparations were performed in both eyes from 
two rats of each group and were enucleated and immersed for 1 h in a solution of 4% 
paraformaldehyde in PBS. Later, the retinas were dissected as whole-mounts by making four 
radial cuts. Retinal orientation was maintained by making the deepest radial cut in the superior 
retina. The retinas were postfixed for 1 h in the same fixative and rinsed in PBS. Cell nuclei 
were counterstained with Hoechst 33342 (Sigma) before mounting with antifading media 
(Invitrogen) for confocal laser scanning microscopy.  
For immunohistochemical studies on sagittal sections, both eyes from four rats of each 
group were enucleated, and the anterior segments, including the lens, were removed. 
Posterior eyecups were fixed for 1 h with 4% paraformaldehyde in 0.1 M PBS followed by 
several washes in PBS. Samples were then immersed in 30% sucrose in PBS overnight at 4 °C 
for cryoprotection. Eyecups were embedded and oriented in optimal cutting temperature 
(O.C.T.) compound (Tissue- Tek; Sakura Finetek Europe B.V., Alphen and den Rijn, The 
Netherlands) and frozen in 2-methylbutane cooled in liquid nitrogen at −60 °C. Radial sections 
(16 μm) were cut on a cryostat and mounted on SuperFrost Plus microscope slides (VWR 
International bvba, Leuven, Belgium). Tissue sections were washed with PBS and blocked with 
blocking solution (0.05% Triton X-100, 10% donkey serum, 3% BSA in PBS) for 1 h. Sections 
were incubated in primary antibodies: mouse anti- GFP (1:100; Life Technologies), rabbit anti-
PKC (1:100, Santa Cruz Bioterchnologies), rabbit antirecoverin (1:400, Millipore), rabbit anti-
NeuN (1:300, Millipore), goat antivimentin (1:100, Santa Cruz Bioterchnologies). Incubation 
was carried out overnight at room temperature in a humidified chamber followed by rinsing in 
PBS. Sections were then incubated with fluorescent specifics-secondary antibodies Alexa Fluor 
488 donkey antimouse IgG, Alexa Fluor 555 donkey antirabbit IgG, and Alexa Fluor 555 donkey 
antigoat IgG (Life Technologies) at a 1:100 dilution for 1 h at room temperature in the dark. 
Sections were counterstained with Hoechst 33342 (Sigma) and mounted with antifading 
mounting medium. The specimens were examined with a laser scanning confocal microscope 
(Leica TCS SPE). 
 
2.9. Statistical Analysis.  
Statistical analysis was completed with the InStat program (GraphPad Software, San 
Diego, CA, USA). Differences between groups at significance levels of 95% were calculated by 
the Student’s t test. In all cases, P values <0.05 were regarded as significant. Normal 
distribution of samples was assessed by the Kolmogorov−Smirnov test and the homogeneity of 
the variance by the Levene test. Data were presented as mean ± SD unless stated otherwise. 
 
  
 
Figure 1. Agarose gel electrophoresis studies. (A) Binding efficiency (lanes 2−7) and release 
(lanes 8−13) of DNA at different protamine/DNA ratios (w/w). Lane 2 = 0.25:1; lane 3 = 0.5:1; 
lane 4 = 1:1; lane 5 = 2:1; lane 6 = 3:1; lane 7 = 4:1. Vectors were treated with SDS to release 
the DNA at different protamine/DNA ratios (w/w). Lane 8 = 0.25:1; lane 9 = 0.5:1; lane 10 = 
1:1; lane 11 = 2:1; lane 12 = 3:1; lane 13 = 4:1. Lane 1 = free DNA; lane 14 = free DNA + SDS. (B) 
Binding efficiency of DNA with niosomes (lanes 2−7) and with protamine/DNA/niosomes 
vectors (lanes 8−13) at different ratios of niosome/DNA (w/w) and protamine/DNA/niosome 
(w/w/w). Lane 2 = 1:1; lane 3 = 2:1; lane 4 = 5:1; lane 5 = 10:1; lane 6 = 15:1; lane 7 = 30:1; lane 
8 = 1:1:1; lane 9 = 1:1:2; lane 10 = 1:1:5; lane 11 = 1:1:10; lane 12 = 1:1:15; lane 13 = 1:1:30. 
Lane 1 and lane 14 = free DNA. (C) Release of DNA from niosomes (lanes 2−7) and from 
protamine/DNA/niosomes vectors (lanes 8−13) after the addition of SDS at different ratios of 
niosome/DNA (w/w) and protamine/DNA/niosome (w/w/w). Lane 2 = 1:1; lane 3 = 2:1; lane 4 
= 5:1; lane 5 = 10:1; lane 6 =15:1; lane 7 = 30:1; lane 8 = 1:1:1; lane 9 = 1:1:2; lane 10 = 1:1:5; 
lane 11 = 1:1:10; lane 12 = 1:1:15; lane 13 = 1:1:30; lane 1 = free DNA, lane 14 = free DNA + 
SDS. (D) Protection of DNA by niosomes (lanes 2−7) and by protamine/DNA/niosomes (lanes 
8−13) from DNase enzymatic digestion at different ratios of niosome/DNA (w/w) and 
protamine/DNA/niosome (w/w/w). After DNase incubation, SDS was added to release the 
DNA. Lane 2 = 1:1; lane 3 = 2:1; lane 4 = 5:1; lane 5 = 10:1; lane 6 = 15:1; lane 7 = 30:1; lane 8 = 
1:1:1; lane 9 = 1:1:2; lane 10 = 1:1:5; lane 11= 1:1:10; lane 12 = 1:1:15; lane 13 = 1:1:30; lane 1 
= free DNA + DNase; lane 14 = free DNA. OC, open circular form; SC, supercoiled form. 
 
3. RESULTS 
 
3.1. Condensation, SDS-Induced Release of DNA, and DNase I Protection Assays.  
The gel in Figure 1, panel A shows that the capacity of protamine to condense DNA depends 
strongly on the protamine/DNA ratio. In wells 2 and 3 (protamine/DNA ratios of 0.25:1 and 
0.5:1), the strong intensity of the SC bands (comparable to free DNA on wells 1 and 14) 
indicates that most of the DNA was free. In well 4 (protamine/DNA ratio of 1:1), faint SC band 
indicates that part of the DNA was not strongly complexed with the protamine. However, from 
wells 5 to 7 (protamine/DNA ratios of 2:1, 3:1, and 4:1, respectively), no DNA migration was 
observed, which indicates that at these ratios the DNA was strongly bound to the protamine. 
After treatment of the complexes with SDS (wells 8−14), the release of DNA was decreased as 
the protamine/DNA ratio increased. The capacity of the niosome vectors to bind DNA is 
illustrated in Figure 1, panel B. DNA bands on wells 2−4 (niosome/DNA ratios of 1:1, 2:1, and 
5:1) indicate that part of the DNA was free. From wells 5 to 7 (niosome/DNA ratios of 10:1, 
15:1, and 30:1), the DNA was totally bound to the niosomes since no SC DNA bands were 
observed. Regarding the capacity of protamine/ DNA/niosome vectors to bind the DNA (wells 
8−13), the faint bands of DNA observed in wells 8 and 9 indicate that at 
protamine/DNA/niosome ratios of 1:1:1 and 1:1:2, part of the DNA was not tightly complexed 
with the vectors. However, as the mass ratio of the complexes increased, (wells 10−13 that 
correspond to protamine/DNA/niosome ratios of 1:1:5 and 1:1:10 and 1:1:15 and 1:1:30, 
respectively), stronger complexes were formed and detained in the wells, hampering the 
migration of the DNA through the gel. Wells 1 and 14 correspond to free DNA. The release of 
the DNA upon the addition of SDS was examined in Figure 1, panel C. DNA release from 
niosomes (well 2−7) was successfully achieved at all ratios (from 1:1 to 30:1), although in well 
7 (niosome/DNA ratio of 30:1), part of the DNA did not migrate and was retained in the well. 
Regarding the capacity of SDS to release DNA from protamine/DNA/niosome vectors (wells 
8−13), free DNA bands were observed at low mass ratios (wells 8−10, which correspond to 
ratios of 1:1:1, 1:1:2, and 1:1:5). However, when the mass ratio of the complexes increased 
(wells 11−13, which correspond to ratios of 1:1:10, 1:1:15, and 1:1:30, respectively), stronger 
complexes were formed hampering the migration of the plasmid, even upon the addition of 
SDS. Well 1 corresponds to free DNA and well 14 to free DNA treated with SDS. DNA protection 
from enzymatic digestion was analyzed in Figure 1, panel D. The absence of bands on wells 2 
and 3 (niosome/DNA ratios of 1:1 and 2:1) indicates that the plasmid was completely degraded 
by the enzyme, as succeeded in well 1 (free DNA treated with DNase I). As the niosome/ DNA 
ratio increased (5:1, 10:1, and 15:1, which correspond to wells 4, 5, and 6), more intense SC 
bands were observed. At 30:1 ratio (well 7), part of the protected DNA was detained in the 
well. Regarding protamine/DNA/niosome vectors (wells 8−13), the SC bands were more 
intensive as the mass ratio of the complexes increased (wells 8−10, which correspond to ratios 
of 1:1:1, 1:1:2, and 1:1:5). However, at higher mass ratios (wells 11−13, ratios of 1:1:10, 1:1:15, 
and 1:1:30, respectively), part of the protected DNA was retained in the well and did not 
migrate through the agarose matrix. Well 14 correspond to free DNA. 
 
3.2. Particle Size, Zeta Potential, and TEM of the Vectors.  
Vectors were physicochemically characterized in terms of size, zeta potential, and morphology 
(Figure 2). As shown in Figure 2, panel A1, the particle size of protamine/ DNA complexes 
decreased as the protamine/DNA ratio increased (210 nm at 0.25:1 mass ratio, and 125 nm at 
4:1 mass ratio). By contrast, zeta potential value increased proportionally to the mass ratio 
(−30 mV at 0.25:1 mass ratio, and 16 mV at 4:1 mass ratio). Protamine/DNA complexes at 1:1 
mass ratio exhibited a heterogeneous morphology when assessed by TEM, as illustrated in 
Figure 2, panel A2. Regarding niosome/DNA binary vectors, particle size also decreased with 
the mass ratio from 180 nm at 1:1 mass ratio to 135 nm at 30:1 mass ratio (Figure 2B1). 
Negative zeta potential values were observed at low niosome/DNA ratios (−31 mV and −23 mV 
at 1:1 and 2:1 mass ratios, respectively). First positive zeta potential value (30 mV) was 
observed at 5:1 mass ratio, and from this point, zeta potential slightly increased until a 
maximum of 39 mV at 30:1 mass ratio. At 15:1 niosome/DNA mass ratio, vectors exhibited a 
discrete spherical morphology (Figure 2B2). Ternary protamine/DNA/noisome vectors 
formulated at a fixed protamine/DNA ratio of 1:1, and increasing proportions of niosomes 
slightly changed particle size, which ranged from 160 nm at 1:1:1 protamine/DNA/ niosome 
ratio to 130 nm at 1:1:30 protamine/DNA/noisome ratio (Figure2C1). At 1:1:1 mass ratio, zeta 
potential value was slightly negative (−2.0 mV). The rest of the ratios resulted in positive zeta 
potential values, which ranged from 27 mV at 1:1:2 mass ratio to 43 mV at 1:1:30 mass ratio. 
Discrete spherical shapes were observed when protamine/DNA/ niosome ternary vectors were 
examined under TEM (Figure 2C2). 
 
 
 
Figure 2. Vectors characterization in terms of particle size, zeta potential, and morphology at 
different mass ratios. (A1) Effect of protamine/DNA ratio on particle size (bars) and zeta 
potential (lines). (mean ± SD, n = 3). (A2) TEM image of protamine/DNA vectors at 1:1 mass 
ratio. Original magnification 88.000×. Scale bar = 200 nm. (B1) Effect of niosome/DNA ratio on 
particle size (bars) and zeta potential (lines). (mean ± SD, n = 3). (B2) TEM image of 
niosome/DNA vectors at 15:1 mass ratio. Original magnification 88.000×. Scale bar = 200 nm. 
(C1) Effect of protamine/DNA/ niosome ratio on particle size (bars) and zeta potential (lines). 
(mean ± SD, n = 3). (C2) TEM image of protamine/DNA/niosome vectors (1:1:5 mass ratio). 
Original magnification 88.000×. Scale bar = 200 nm. 
 
 
 
 
 
 
 
 
  
 
Figure 3. Transfection efficiency of niosome/DNA (15:1, w/w ratio) and 
protamine/DNA/niosome (1:1:5, w/w/w ratio) vectors at different times after the addition of 
the vectors in ARPE-19 cells. (A) Bars represent the percentage of transfected cells after the 
addition of niosome/DNA vectors (white bars) and protamine/DNA/niosome vectors (black 
bars). Lines represent the percentage of viable cells after the addition of niosome/DNA DNA 
(white circles) and protamine/DNA/niosome vectors (black circles). Mean ± SD; n=3. (*P<0.01; 
**P<0.001). (B) Mean fluorescent intensity (MFI) of cells transfected with niosome/DNA (white 
bars) and protamine/DNA/niosome vectors (black bars). Mean ± SD; n=3. (#P<0.01; ##P 
<0.001; ###P<0.0001). (C1-C3) Flow cytometry dot-plots (FL1-FL3), histograms (FL1), and 
overlay phase-contrast micrograph with fluorescent illumination (GFP channel) of cells 
transfected with niosome/DNA vectors. (D1-D3) Flow cytometry dot-plots (FL1-FL3), 
histograms (FL1), and overlay phase-contrast micrographs with fluorescent illumination (GFP 
channel) of cells transfected with protamine/DNA/niosome vectors. FL1 channel corresponds 
to EGFP and FL3 channel to 7-AAD. Original magnification 20x.  
 
3.3. Transfection and Cell Viability Studies.  
Transfection efficiency and cell viability over time were studied in ARPE-19 cells (Figure 3). As 
observed in Figure 3, panel A, the percentages of transfected cells (bars) were higher with the 
ternary vectors containing protamine at all the evaluated times. Statistical differences 
between both groups were obtained at 48, 72, 96, and 168 h post-transfection. The maximum 
percentage of transfected cells was obtained at 72 h post-transfection for both niosome/DNA 
(19%) and protamine/DNA/noisome (26%) vectors. Both values were clearly inferior to those 
previously reported when commercial Lipofectamine 2000 was used to transfect ARPE-19 cells, 
around 50%.29 Regarding cell viability (Figure 3A, lines), niosome/DNA binary vectors were 
significantly more toxic to ARPE-19 cells 48 h post-transfection until the end of the experiment. 
In any case, cell viability was over 94% in all the studied conditions, a value clearly superior to 
that obtained when ARPE-19 cells were transfected with Lipofectamine 2000 (around 75%, 
data not shown). To further relate the percentage of transfected cells and the level of protein 
expression, we measured the mean fluorescent intensity (MFI) of transfected cells (Figure 3B). 
For both formulations, MFI increased gradually from 48 to 72 h post-transfection, and at this 
point, MFI reached the maximum value and decreased gradually until the end of the 
experiment. At all tested times, MFI of protamine/DNA/niosome ternary vectors was 
significantly higher when compared with niosome/DNA binary vectors. Under microscopic 
examination, ARPE-19 cells exhibited a healthy morphology at 72 h post-transfection with both 
niosome/DNA and protamine/DNA/niosome vectors (Figure 3C3 and D3, respectively). Figure 
3, panels C1 and C2 represent flow cytometry dot-plots (FL1−FL3) and histograms (FL1) of 
ARPE-19 cells at 72 h post-transfection with niosome/ DNA vectors. Similarly, Figure 3, panels 
D1 and D2 represent flow cytometry dot-plots (FL1−FL3) and histograms (FL1) of cells at 72 h 
post-transfection with ternary protamine/DNA/ niosome ternary vectors. 
 
3.4. Detection of Intracellular EMA Labeled DNA by Fluorescence Microscopy.  
Figure 4 represents fluorescent images of ARPE-19 cells 2 h after the addition of naked 
DNA (Figure 4A1−A4), binary niosome/DNA vectors at 15:1 mass ratio (Figure 4B1−B4), and 
ternary protamine/DNA/noisome vectors at 1:1:5 mass ratio (Figure 4C1−C4) containing EMA 
labeled DNA. The absence of red fluorescence in Figure 4, panel A3 suggests that the plasmid 
was not internalized by the cells when added alone. At high magnification, we observed a 
homogeneous distribution of the red fluorescence in the cytoplasm and nucleus of cells 
treated with niosome/DNA vectors (Figure 4D1); however, when cells were treated with 
protamine/DNA/niosome vectors, the DNA was more condensed, red fluorescence was more 
intense, and the DNA was mainly observed inside the nucleus rather than in the cytoplasm 
(Figure 4D2). 
 
 
 
 
  
 
Figure 4. Fluorescent microscopy images of ARPE-19 cells 2 h after the addition of (A1−A4) 
naked-DNA, (B1−B4) niosome/DNA vectors at 15:1 ratio, and (C1−C4) protamine/DNA/niosome 
vectors at 1:1:5 ratio. Blue color shows cell nuclei stained with Hoeschst 33258, and green 
color shows F-actin stained with Phalloidin. Red color shows EMA-labeled pCMS-EGFP plasmid. 
(A4−C4) Merged images of ARPE-19 cells after the addition of naked-DNA, niosome/DNA 
vectors at 15:1 ratio, and protamine/DNA/niosome vectors at 1:1:5 ratio, respectively. Original 
magnification 10×. (D1 and D2) Images at 60× magnification of ARPE-19 cells after the addition 
of niosome/DNA and protamine/DNA/noisome vectors, respectively. 
 
 
  
Figure 5. In vivo gene expression of EGFP after administration of protamine/DNA/niosome 
ternary vectors at 1:1:5 mass ratio to rats 1 month post (A) subretinal and (B) intravitreal 
injections. When ternary vectors were subretinally and intravitreous injected, native EGFP 
expression (in green) was observed in wholemount preparations. (A) Intense GFP+ cell bodies 
accumulations are found in the ganglion cell layer. (B) Many retinal cells show GFP 
fluorescence, and scattered cells show a cytoplasm ganglion cell-like morphology. Cell nuclei 
were counterstaining with Hoechst 33342 (pseudocolored in magenta). GCL, ganglion cell 
layer. Scale bar = 20 μm. 
 
3.5. In Vivo EGFP Expression.  
At 1 month after injection, the optical coherence tomography study of injected eyes 
demonstrated no changes in the retina (Figure 2, Supporting Information) other than a small 
bleed around the injection site (data not shown). Subretinal and intravitreal injections did not 
harm the retinal integrity. There was no evidence of retinal toxicity secondary to 
administrations.  
EGFP expression in rat retinas was detected 14 days and 1 month after subretinal and 
intravitreal administrations of protamine/DNA/niosome ternary vectors at 1:1:5 mass ratio 
(Figures 5−7). The analysis of the native EGFP expression on wholemount retinas after 1 month 
of the administrations revealed EGFP-expressing cells in the ganglion cell layer (Figure 5), and 
no fluorescence was detected in control retinas (data not shown). Retinal wholemounts 
subretinally injected showed accumulations with strong GFP expression close to the site of 
injection in the ganglion cell layer (Figure 5A). In contrast, disperse GFP positive retinal 
ganglion cells were detected in the retina with intravitreal administration (Figure 5B).  
Immunohistochemical staining of GFP and several retinal markers in rat retinas after 
14 days postinjection showed levels of protein expression strongly varied depending on the 
location of the injection (Figure 6). Transfection of RPE cells and photoreceptor layer was most 
efficiently achieved by subretinal administration of ternary vectors (Figure 6A−C). In addition, 
we found some postsynaptic terminal of rod bipolar cells (marked with PKC) contacting with 
processes GFP positive in the inner plexiform layer. Subretinal injection induces a bleb of 
concentrated vector in intimate contact with photoreceptors and RPE; thus, GFP expression 
was mainly observed in the cells close to the place of the injection in the retinal pigment 
epithelium (RPE) (Figure 6A), the photoreceptor outer segments (Figure 6B), and outer nuclear 
layer labeled with recoverin (Figure 6C). After intravitreal injections, we observed GFP 
expression distributed mainly in the ganglion cell layer (GCL) and Müller cells prolongations in 
the inner retina (Figure 6D,E) as well as some processes at the inner nuclear layer (Figure 6D). 
Subsequently, the immunolabeling was perfomed in the contralateral eyes (control eyes), and 
no GFP expression was detected (data not shown).  
The study of the retinas 1 month after subretinal administration revealed GFP 
expression predominantly in ganglion cells (NeuN-positives) and their prolongations (Figure 
7A,B). Additionally, 1 month after intravitreal injection, GFP partially colocalized with Müller 
glial cell labeled with vimentin (Figure 7C). There was no evidence of GFP expression in eyes 
that were used as control. 
 
 
 
Figure 6. Immunohistochemical study of EGFP expression in retinal cross-sections 14 days after 
subretinal and intravitreal administration of protamine/DNA/niosome ternary vectors at 1:1:5 
mass ratio. Doble immunolabeling of (A−C) subretinal and (D,E) intravitreal injection with GFP 
(green), (A) PKC in red, or (B−E) recoverin in red. (A) Confocal image of retinal cross-section 
shows that GFP expression was localized in the retinal pigment epithelium layer, ganglion cell 
layer, and some blood vessel. (B) GFP was localized to some outer segments of 
photoreceptors, and (C) only an occasional photoreceptor double-labeled for GFP and 
recoverin can be found. Panels D and E show GFP signal in ganglion cell layer, and (D) some 
processes in the inner plexiform layer are GFP positive. Cell nuclei were counterstaining with 
Hoechst 33342 (pseudocolored in blue). RPE, retinal pigment epithelium layer; OS, outer 
segments; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, 
inner plexiform layer; GCL, ganglion cell layer. Scale bar = 20 μm. 
 
 
4. DISCUSSION 
Nonviral retinal gene therapy offers reasonable hope to address many devastating 
binding disorders that affect the retina,
7
 although new safe and effective vectors need to be 
developed to be considered as a mainstream medicine option. In a previous work, we have 
already demonstrated the capacity of novel niosomes based on the 2,3-
di(tetradecyloxy)propan-1-amine cationic lipid combined with squalene and polysorbate 80 to 
transfect efficiently the rat retina with the reporter pCMS- EGFP plasmid.18 In this work, we 
evaluated the incorporation of protamine to our niosome formulation to progress in the 
design and develop new nonviral vectors for retinal gene delivery purposes. 
Generally, nonviral vector complexes are formed as a result of the electrostatic 
interactions between the cationic charges of the vectors and the anionic charges of the DNA.
24
 
To further study these electrostatic interactions, we performed an agarose gel electrophoresis 
assay (Figure 1) since an optimum equilibrium between gene condensation and release is 
required to increase transfection efficiency.
20
 As expected, the capacity of protamine to 
condense the DNA depended on the protamine/ DNA ratio (Figure 1A). A protamine/DNA ratio 
of at least 2:1 was required to condense all DNA. At this ratio, the electrostatic interactions 
between protamine and DNA were strong enough to hamper the diffusion of free DNA 
through the agarose matrix (Figure 1A, well 5); however, at a lower ratio (protamine/DNA 1:1, 
well 4), the amount of protamine was not enough to totally condense the DNA. DNA migration 
induced by SDS treatment was hampered as the protamine/ DNA ratio increased. Therefore, 
we selected the 1:1 protamine/ DNA mass ratio as the optimal ratio to further elaborate 
ternary protamine/DNA/niosome vectors. We therefore hypothesize that the unbound DNA at 
this proportion could be further retained in the formulation upon the addition of cationic 
niosomes. Likewise, at this mass ratio, DNA was easily released from protamine (Figure 1A, 
well 10), which is an important factor for gene delivery applications.
24
 Gel electrophoresis 
assay (Figure 1B) also showed that the presence of protamine at 1:1 mass ratio increased the 
DNA condensation capacity of the protamine/DNA/niosome vectors (Figure 1B, well 5); 
however, when protamine was incorporated into the ternary vectors, only a niosome/DNA 
ratio of 5:1 was enough to condense all the DNA in the protamine/DNA/noisome formulation 
(Figure 1B, well 10, 1:1:5 mass ratio). Figure 1, panel C shows that all niosome/DNA ratios, 
except 30:1, were able to release DNA in the presence of SDS; however, ternary vectors 
retained DNA in the wells at niosome/DNA ratios over 10:1 (Figure 1B, well 11, 1:1:10), which 
corroborates the assumption that protamine at 1:1 mass ratio increased the DNA 
condensation capacity. DNA can be easily degraded by nucleases in the cytosol.
30
 Therefore, it 
is essential to study the DNA protection capacity of nonviral carriers to design efficient vectors 
for gene delivery purposes. Figure 1, panel D shows that niosome vectors at 15:1 mass ratio 
were able to protect and release DNA from enzymatic digestion since a clear SC band was 
observed on the gel (Figure1D, well 6). The lower protection capacity (SC bands), observed at 
mass ratios below 15:1, was probably due to a lower condensation degree of the DNA in the 
complexes, which was more exposed to the digestion mediated by the enzymes. At higher 
mass ratios (30:1, Figure 1D, well 7), part of the protected DNA was detained in the well, which 
indicates that the electrostatic interactions were strong enough to hamper the release of the 
DNA. Regarding the ternary vectors, clear SC bands were observed at 1:1:5 
protamine/DNA/niosome mass ratios (Figure 1D, well 10). At higher niosome ratios, the strong 
electrostatic interactions hampered the diffusion of the protected DNA. These results 
emphasize the importance of the delicate balance between DNA condensation capacity to 
protect DNA from DNases, and DNA release, since an excess DNA condensation hampers 
plasmid release and transfection; by contrast, a low condensation will not protect DNA.
31
  
To correlate the agarose gel electrophoresis results with changes in particle size and 
superficial charge of the vectors, we performed DLS and LDV measurements to determine the 
hydrodynamic diameter and the superficial charge of the vectors. Additionally, the morphology 
of the vectors was analyzed by TEM (Figure 2). Adding DNA to the niosomes at a 15:1 
niosome/DNA mass ratio formed lipoplexes, which adopted a discrete spherical morphology 
(Figure 2B2), the most favorable structure from an energetic point of view.
32
 The incorporation 
of protamine in the ternary vectors at a 1:1:5 protamine/DNA/niosome mass ratio did not 
change significantly the morphology (Figure 2C2). In Figure 2, panel A1, we observed, as 
aforementioned in the agarose gel electrophoresis assay, that the capacity of protamine to 
condense the DNA depended on the protamine/DNA mass ratio since particle size of 
complexes clearly decreased as the mass ratio increased (Figure 2A1) due to the stronger 
electrostatic interactions that condense DNA more efficiently. Likewise, the highest zeta 
potential values observed at high mass ratios could explain the stronger electrostatic 
interactions that results in a more efficient DNA condensation, and therefore the size of 
protamine/DNA complexes was reduced.
20
 Interestingly, zeta potential values of 
protamine/DNA complexes at 1:1 mass ratio exhibited a negative zeta potential value of −15 
mV, which could explain the faint SC bands observed in Figure 1, panel A, well 4, because at 
this ratio, the amount of protamine was not enough to condense all the DNA. Additionally, 
negative zeta potential value of protamine/DNA complexes at 1:1 mass ratio could enhance 
electrostatic interactions with cationic niosomes when these are added to formulate 
protamine/DNA/niosome ternary vectors. From Figure 2, panel B1, we observed that niosome/ 
DNA vectors required a 5:1 mass ratio to achieve the first positive zeta potential values (Figure 
2B1) and retain most of the DNA (Figure1B, well 4); however, when protamine was 
incorporated to formulate protamine/DNA/niosome ternary vectors, only a 2:1 niosome/DNA 
ratio was required to obtain positive zeta potential values (Figure 2C1) and condense most of 
the DNA (Figure1B, well 9). The smaller amount of niosome required to obtain positive zeta 
potential values in ternary vectors can be attributed to the partial neutralization between the 
anionic DNA and the positive protamine.  
Regarding particle size, we observed that ternary vectors were smaller than the 
counterpart niosome/DNA binary vectors at all tested ratios, which corroborates the 
assumption that DNA is more condensed when protamine is added to the formulation. 
Although it has been described that the size of nanoparticles clearly rules cellular uptake and 
therefore transfection efficiency,
33,34
 nowadays there is not a clear consensus about the 
optimum particle size of nonviral vectors for gene delivery purposes. In any case, the sizes of 
the vectors reported in our work slightly ranged from 120−180 nm at different conditions 
(Figure 2B1,C1) and clearly were into the nanorange scale, which has been reported that 
enhances intracellular uptake when compared with the microrange scale.
35
 The surface charge 
of nonviral vectors is another parameter that needs to be considered. A final positive charge 
on the surface of the vectors is a desirable condition since it enhances electrostatic 
interactions with negatively charged cellular membranes and the posterior uptake into the 
cell.
20
  
On the basis of the physicochemical characteristics of the vectors in terms of DNA 
condensation, protection, release, particle size, morphology, and superficial charge, we 
selected niosome/DNA binary and protamine/DNA/niosome ternary vectors at 15:1 and 1:1:5 
mass ratios respectively for in vitro transfection studies in ARPE-19 cells. At these ratios, both 
vectors were able to condense, protect, and release the DNA. Additionally, cationic spherical 
nanoparticles were obtained with adequate characteristics for gene delivery applications.  
ARPE-19 cells represent a good in vitro model to evaluate transfection systems aimed 
to treat inherited retinal diseases. These cells play a major role in ocular inherited diseases 
associated with senescence and dystrophies of the photoreceptors and mutations in genes of 
these cells can lead to photoreceptor death.
36
 In addition, these cells divide slowly, which 
could explain the difficulties found by some authors to get high transfection efficiencies
37
 since 
the passage of the DNA into the nucleus is hampered in slowly dividing cells as ARPE-19.
38
 
Therefore, to transfect efficiently this cell line, we incorporated to our niosome formulation 
protamine at an appropriate mass ratio based on our previous characterization studies and 
because of the reported flattering properties of protamine to promote active nuclear transport 
through the nuclear pore complex due to the rich sequences in arginine.
19
 However, 
protamine/DNA vectors by themselves were not able to transfect ARPE-19 cells (data not 
shown), which is in agreement with data reported by other authors.
20,21
 One possible reason 
may be the high hydrophilicity of the protamine, which could hamper the entry through 
cellular membrane.
21
 To overcome this scenario, we prepared protamine/ DNA/niosome 
ternary vectors, and the transfection efficiency and cell viability of this formulation on ARPE-19 
cells were compared with niosome/DNA binary vectors (Figure 3). Interestingly, we observed 
that the percentage of transfection and the cell viability was statistically higher in ternary 
vectors (Figure3A). However, in rapidly dividing cells such as HEK- 293, in which nuclear entry 
should not be a limiting factor for transfection efficiency due to the nuclear membrane 
disruption during the mitosis process, the incorporation of protamine did not increase 
transfection efficiency.
20
 These results suggest that the addition of protamine to lipid-based 
formulations could be an interesting approach to increase transfection in slowly dividing cells 
and probably in postmitotic cells found in the retina. To have some evidence of the level of 
protein expression, we also measured the MFI of the transfected cells (Figure 3B). Our results 
showed that the MFI of transfected cells by ternary protamine/DNA/niosome vectors was 
statistically higher when compared with the binary vectors. Therefore, we can conclude that 
the incorporation of protamine
39
 to niosome/DNA vectors not only increased the percentage 
of transfected cells, but also the amount of protein expression, which has significant relevance 
for clinical applications. Regarding the cytotoxic effect of the formulations, we observed that 
protamine/DNA/niosome ternary vectors at 1:1:5 mass ratio were clearly better tolerated by 
ARPE-19 cells than their counterparts niosome/DNA binary vectors at 15:1 mass ratio 
(Figure3A, lines). Classically, the toxicity of lipoplexes has been associated with the induction 
of apoptosis and has been clearly correlated with the amount of the cationic lipid in the 
formulation.
40
 Our protamine/DNA/niosome ternary vectors were formulated at a 
niosome/DNA ratio of 5:1, three-times lower that the 15:1 mass ratio of the binary vectors, 
which could explain its lower cytotoxicity. Therefore, protamine/ DNA/niosome ternary 
vectors at 1:1:5 mass ratio transfected ARPE-19 cells more efficiently than the binary vectors 
based niosome/DNA at 15:1 mass ratio and were better tolerated by the these cells.  
To explain the differences observed in the transfection efficiency between both binary 
and ternary vectors in ARPE-19 cells, we investigated the intracellular distribution of DNA in 
both binary vectors (niosome/DNA, 15:1 mass ratio) and ternary vectors 
(protamine/DNA/niosome, 1:1:5 vectors) 2 h after the addition of the formulations. For this 
purpose, DNA was labeled with EMA, a red fluorescent DNA intercalating agent. As observed in 
Figure 4, the DNA was much more condensed after the treatment of the cells with the 
formulation containing protamine (Figure 4D2). In addition, most of the DNA was inside the 
nucleus. By contrast, the binary formulation without protamine presented a more 
homogeneous distribution of the DNA through the nucleus and cytoplasm. These findings 
confirm the excellent properties of protamine to improve DNA packaging (which prevents 
degradation by different cytoplasmic agents such as DNases) and promote DNA delivery into 
the nucleus by means of nuclear localization sequences.
24,41
 This issue is especially important in 
slow dividing cells, such as ARPE-19, since the entry of DNA into the nucleus is hampered by 
the nuclear membrane. However, differences on transfection efficiencies between both binary 
and ternary vectors could be due to not only the nuclear enhancing properties of protamine 
into slow dividing cells, but also to the differences on the endocytosis mechanism. For 
instance, it has been reported that the components of the formulation such as sweet arrow 
peptide and dextran may have particular features to change the endocytosis mechanism and, 
consequently, the transfection efficiency when they are added to lipid-based formulations.
38,42
 
Regarding protamine, it has been reported that it can change the internalization route when 
added to solid lipid nanoparticles in a clear cell-dependent manner.
20
 Interestingly, in this last 
study, authors observed a shift in the internalization pathway from caveolae/raft-mediated to 
clathrin- mediated endocytosis in ARPE-19 cells when protamine was incorporated into DNA-
SLN vectors. Genes internalized by clathrin-mediated endocytosis pathway are usually 
entrapped in endosomes, which fuse with lysosomes and result in the degradation of the 
content.43 Therefore, to get efficient gene expression through this pathway, a timely release 
of the DNA from the endosome into the cytoplasm is required. We have recently reported that 
incorporation of squalene (a precursor of the cholesterol synthesis) to our cationic niosome 
formulation could enhance endosomal scape, resulting in high levels of gene expression when 
clathrin-mediated endocytosis commands the internalization process.
18
 By contrast, the lack of 
lysosomal activity in the caveosomes could explain, at least in part, the lower transfection 
efficiency found in ARPE-19 cells when caveolae mediated endocytosis is involved in the 
internalization mechanism since the release of the DNA from the niosome can be hampered 
when particles are internalized by this route. Therefore, we hypothesize that a similar shift in 
the internalization pathway from caveolae/raft-mediated to clathrin- mediated endocytosis 
could happen when protamine is added to our niosome/DNA vectors. However, and 
considering that one of the main roles of ARPE-19 cells is the phagocytosis of shed 
photoreceptors, the phagocytic capacity and other endocytic routes of ARPE-19 cells (up to 
nine different endocytosis routes have been differentiated) should be also considered to 
further analyze the role of protamine on transfection efficiency mediated by niosomes.  
We carried out a preliminary in vivo study to evaluate the transfection efficiency and 
toxicity of protamine/DNA/ niosome ternary vectors at 1:1:5 mass ratio 14 days after 
intravitreal and subretinal injections. Gene delivery by intravitreal injection has been 
extensively studied as a relatively easy way to deliver high doses in the retina structures. 
Classically, after intravitreal injection, high protein expression is typically observed in the 
ganglion cell layer and in some cells of the inner nuclear layer,
39,44
 which is in agreement with 
data observed 14 days after intravitreal administration in Figure 6, panels D and E, where some 
ganglion and their processes and Müller cells expressed the green fluorescent protein. 
Transfection at this level could have relevant clinical implication for the treatment of 
glaucoma, which is the first cause of visual disability and blindness worldwide. However, one 
of the biggest challenges of intravitreal injection is to target the outer segments of the 
photoreceptors and the RPE without causing harm to the sensitive neural tissue
7
 since most of 
the inherited retinal diseases such as Stargat Disease, Retinitis Pigmentosa, Age-related 
Macular Degeneration, or Leber Congenital Amaurosis are due to defects of genes at this 
level.
45
 By contrast, injections of vectors into the subretinal space allow the direct contact of 
the nucleic acids with photoreceptors, outer retinal layers, and RPE cells.
46
 Therefore, this 
route of administration could be appropriate to treat the aforementioned retinal inherited 
diseases. However, there is a high risk of retinal detachment or lesion in the retina after 
subretinal injection. In any case, promising results have been obtained in clinical trial after 
subretinal injection to treat many inherited retinal diseases such as Leber Congenital 
Amaurosis Type 2.
47
 As observed in Figure 6, panels A−C, we found high levels of protein 
expression in photoreceptors (and outer segments) and in the RPE 14 days after subretinal 
injection. We further evaluated transfection efficiency 1 month after both intravitreal and 
subretinal injections since long-term transgene expression is integral to success of any gene 
therapy intervention to reduce the frequency of invasive intravitreal and subretinal 
administration to patients affected. After 1 month of both subretinal and intravitreal 
injections, we observed a decrease in the number of cells transfected (Figures 5 and 7), 
probably due to the episomal nature of the plasmid and gene silencing procedures. However, 
when time is a crucial factor, we should consider important differences in anatomy, 
physiology, development, and biological phenomena between rats and humans. For instance, 
it has been estimated 30 days of human life for every day of life of the rat.
48
 Taking into 
account these considerations, we can argue that persistence of transfection efficiency 14 days 
and 1 month after the injections in rats is a reasonable period of time to think on clinical 
translation. In any case, different strategies (that actually are out of the scope of the present 
work) to optimize the plasmid design, such as promoter, minicircles, or CpG free plasmids, 
should be considered to enhance the persistence of the gene expression.
3
  
Another concern to be considered in the design of novel nonviral vectors based on 
cationic lipids is the toxicity of the formulation. One of the most widely employed commercial 
liposome reagents for in vitro transfection studies is Lipofectamine 2000. However, both in 
vivo subretinal and intravitreal injections of lipofectamine induce high toxicity in different 
layers of the retina even at low concentrations.
17
 Therefore, although lipofection technology 
remains widely popular for in vitro applications, tissue toxicity at the retina represents an 
important handicap that prevents its use in clinical trials. The in vivo OCT study can enhance 
visualization of morphologic features and could be used to evaluate the integrity of retina. SD-
OCT shows a cross-section of the retina, which appears as a histological slice perpendicular to 
the fundus and allows us to detect retinal pathologies or anomalous structures. In our SDOCT 
study, retinal morphologies were normal without any sign of toxicity associated with the 
formulations on high-resolution spectral OCT scans after one month post subretinal or 
intravitreous administration (see Supporting Information, Figure 2). 
 
 
 
Figure 7. Immunohistochemical analysis of EGFP expression in retinal frozen sections 1 month 
after subretinal and intravitreal administration of protamine/DNA/niosome ternary vectors at 
1:1:5 mass ratio. Double labeling on the (A,B) subretinal and (C) intravitreal injection. Retinal 
sections were performed with GFP (green) and NeuN or vimentin (red). (A,B) GFP 
immunofluorescent staining of retinal sections was predominantly in ganglion cell layer and 
nerve fiber layer and (C) partial colocalization with the Müller glia cell marker vimentin. Cell 
nuclei were counterstaining with Hoechst 33342 (pseudocolored in blue). ONL, outer nuclear 
layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, 
ganglion cell layer. Scale bar = 20 μm. 
 
 
5. CONCLUSIONS. 
This work describes a novel nonviral formulation for efficient gene delivery to the retina. 
Protamine/DNA/niosome ternary vectors at 1:1:5 mass ratio were physicochemically 
characterized in terms of particle size, morphology, superficial charge, and capacity to 
condense, protect, and release the DNA. In vitro transfection experiments were performed in 
ARPE-19 cells. Interestingly, the incorporation of protamine to the niosome/ DNA formulation 
reduced the proportion of cationic lipid to transfect efficiently ARPE-19 cells, which resulted in 
a less toxic formulation when compared with their counterparts niosome/ DNA vectors. 
Moreover, the addition of protamine promoted DNA delivery into the nucleus, which is 
especially relevant in cells with low division rate such as retinal cells. After 1 month of ocular 
administration of ternary vectors, EGFP expression was detected in different cell layers of the 
retina depending on the administration route without any sign of toxicity associated with the 
formulations. While subretinal administration transfected mainly photoreceptors and retinal 
pigment epithelial cells at the site of injection, intravitreal administration produced a more 
uniform distribution of the protein expression through the inner layers of the retina. Our study 
highlights the flattering properties of protamine/DNA/niosome ternary vectors for efficient 
and safe gene delivery to the rat retina. 
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